Polyphor Ltd and Axxam SpA Announce Ion Channel Collaboration
Polyphor Ltd – a clinical stage biotech company applying its proprietary drug discovery research platforms to address protein-protein interactions and other challenging targets and Axxam SpA – a leading company in conducting early-stage discovery research programs for the life science industry, are pleased to announce a joint discovery agreement with a synergistic combination of their discovery platforms.
Under the terms of the collaboration the two companies will work together to discover and develop innovative drug candidates for selected therapeutic areas such as pain, inflammation, and metabolic disorders. Axxam will apply its expertise and outstanding Hit Discovery platforms and capabilities and Polyphor will provide its unique, proprietary PEM finder® library for screening together with its expertise in medicinal chemistry, drug discovery and development. The collaboration comprises several discovery programs addressing very attractive ion channel based targets.